0000950170-24-012962.txt : 20240208 0000950170-24-012962.hdr.sgml : 20240208 20240208191913 ACCESSION NUMBER: 0000950170-24-012962 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240206 FILED AS OF DATE: 20240208 DATE AS OF CHANGE: 20240208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Renger John CENTRAL INDEX KEY: 0001830363 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 24610758 MAIL ADDRESS: STREET 1: C/O CEREVEL THERAPEUTICS, INC. STREET 2: 51 ASHTOR PLACE CITY: NEW YORK STATE: NY ZIP: 10003 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 ownership.xml 4 X0508 4 2024-02-06 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001830363 Renger John C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 false true false false Chief Scientific Officer false Common Stock 2024-02-06 4 M false 5020 A 8531 D Common Stock 2024-02-07 4 S false 2161 41.5441 D 6370 D Restricted Stock Units 2024-02-06 4 M false 5020 0.00 D Common Stock 5020 15061 D Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. Includes 807 shares previously acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.42 to $41.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. /s/ Mark Bodenrader, as Attorney-in-Fact 2024-02-08